Stuttgart - Delayed Quote EUR

TherapeuticsMD, Inc. (29TA.SG)

0.8450

0.0000

(0.00%)

As of 8:00:23 AM GMT+2. Market Open.

TherapeuticsMD Full Year 2024 Earnings: US$0.20 loss per share (vs US$0.74 loss in FY 2023)

TherapeuticsMD ( NASDAQ:TXMD ) Full Year 2024 Results Key Financial Results Net loss: US$2.31m (loss narrowed by 70...

Simply Wall St. 16 days ago

TXMD
TherapeuticsMD Announces Full Year 2024 Financial Results

BOCA RATON, Fla., March 27, 2025--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2024.

Business Wire 18 days ago

TXMD
3 Promising US Penny Stocks With Over $9M Market Cap

As the U.S. stock market looks to recover from a recent losing streak, with major indices like the Dow Jones and Nasdaq showing signs of strength, investors are exploring diverse opportunities across various sectors. Penny stocks, though sometimes overlooked due to their historical connotations, remain a viable investment option when backed by strong financials. In this article, we explore three penny stocks that exhibit financial robustness and potential for growth, offering investors a...

Simply Wall St. 3 months ago

ME

TXMD

EB
TherapeuticsMD Third Quarter 2024 Earnings: US$0.049 loss per share (vs US$0.13 loss in 3Q 2023)

TherapeuticsMD ( NASDAQ:TXMD ) Third Quarter 2024 Results Key Financial Results Net loss: US$567.0k (loss narrowed by...

Simply Wall St. 4 months ago

TXMD
TherapeuticsMD: Q3 Earnings Snapshot

BOCA RATON, Fla. AP) — TherapeuticsMD Inc. TXMD) on Tuesday reported a loss of $609,000 in its third quarter.

Associated Press Finance 4 months ago

TXMD
TherapeuticsMD Announces Third Quarter 2024 Financial Results

BOCA RATON, Fla., November 12, 2024--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2024.

Business Wire 4 months ago

TXMD
TherapeuticsMD: Q2 Earnings Snapshot

BOCA RATON, Fla. AP) — TherapeuticsMD Inc. TXMD) on Monday reported a loss of $1.1 million in its second quarter.

Associated Press Finance 7 months ago

TXMD
TherapeuticsMD Announces Second Quarter 2024 Financial Results

BOCA RATON, Fla., August 12, 2024--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2024.

Business Wire 7 months ago

TXMD
TherapeuticsMD Announces First Quarter 2024 Financial Results

BOCA RATON, Fla., May 10, 2024--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2024.

Business Wire 10 months ago

TXMD

Performance Overview

Return	29TA.SG	S&P 500 (^GSPC)
YTD	-17.96%	-8.09%
1-Year	-54.08%	+6.80%
3-Year	-93.46%	+23.07%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

TherapeuticsMD, Inc. (29TA.SG)

TherapeuticsMD Full Year 2024 Earnings: US$0.20 loss per share (vs US$0.74 loss in FY 2023)

TherapeuticsMD Announces Full Year 2024 Financial Results

3 Promising US Penny Stocks With Over $9M Market Cap

TherapeuticsMD Third Quarter 2024 Earnings: US$0.049 loss per share (vs US$0.13 loss in 3Q 2023)

TherapeuticsMD: Q3 Earnings Snapshot

TherapeuticsMD Announces Third Quarter 2024 Financial Results

TherapeuticsMD: Q2 Earnings Snapshot

TherapeuticsMD Announces Second Quarter 2024 Financial Results

TherapeuticsMD Announces First Quarter 2024 Financial Results

Performance Overview